Uncategorized
CJC-1295 DAC vs No-DAC (Mod GRF 1-29): Complete Comparison Guide
CJC-1295 DAC vs No-DAC (Mod GRF 1-29): The Complete Comparison Guide
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous GH secretion. It exists in two main research forms — with and without Drug Affinity Complex (DAC) — which differ dramatically in half-life, dosing frequency, and effect profile. This guide compares CJC-1295 DAC and No-DAC (also known as Mod GRF 1-29) to help researchers choose the right protocol.
1. What Are the Two Forms?
CJC-1295 is a modified GHRH analog (with amino acid substitutions and the addition of DAC to one form) that binds to the GHRH receptor on pituitary somatotrophs, stimulating GH pulse amplitude. The DAC version extends the peptide’s half-life from minutes to days through albumin binding.
- No-DAC (Mod GRF 1-29): Short-acting GHRH analog; half-life ~30 minutes; dosed 1-3 times daily
- With DAC: Long-acting version; half-life ~5-8 days; dosed 1-2 times per week
- Administration: Subcutaneous injection for both
- Core function: Stimulate endogenous GH release via GHRH receptor
2. Mechanism of Action
Both forms act through the same receptor but differ in pharmacokinetics:
- GHRH receptor activation: Stimulates pituitary release of growth hormone
- DAC (albumin binding): The DAC moiety binds serum albumin, creating a long-acting depot effect
- No-DAC pulse profile: Produces sharp, short GH pulses — closer to natural episodic secretion
- GH-IGF-1 axis: Both increase circulating GH and downstream IGF-1 levels
3. Head-to-Head Comparison
| Parameter | CJC-1295 No-DAC (Mod GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Half-life | ~30 minutes | ~5-8 days |
| Dosing frequency | 1-3x daily | 1-2x weekly |
| GH pulse profile | Sharp, short pulses | Sustained elevation |
| Common pairing | Ipamorelin (synergistic pulse) | Solo or with GHRP analogs |
| Desensitization risk | Lower | Higher (continuous receptor stimulation) |
| Protocol flexibility | High (timing matters) | Lower (fixed weekly schedule) |
4. Research Applications
- GH pulse research: No-DAC used to model episodic GH secretion
- Sustained elevation research: DAC used for prolonged GH-IGF-1 axis activation studies
- Combination protocols: No-DAC commonly paired with Ipamorelin; see our CJC-1295 + Ipamorelin combination guide
- Recovery and body composition research: Both used in muscle recovery and metabolic protocols
For the broader GHRP/GHRH landscape, see our growth hormone-releasing peptides guide and the CJC-1295 vs Ipamorelin comparison.
5. Dosing and Protocol Notes
- No-DAC typical dose: 100-200 mcg, 1-3 times daily, usually before training or bedtime
- DAC typical dose: 1-2 mg, 1-2 times per week
- Reconstitution: Use bacteriostatic water; see our reconstitution and dosage guide
- Timing: No-DAC should be dosed on an empty stomach; DAC timing is less critical
6. Side Effects and Considerations
- Injection site reactions: Common to both forms
- Water retention and joint pain: More common with DAC due to sustained GH elevation
- Desensitization: DAC’s continuous stimulation may reduce receptor sensitivity over time
- Blood glucose effects: GH elevation can affect glucose handling; monitor in research protocols
7. Frequently Asked Questions
Which form is better? It depends on the research goal: No-DAC suits episodic pulse studies and daily protocols; DAC suits sustained elevation and infrequent dosing.
Is DAC a real growth hormone? No — both forms are GHRH analogs that stimulate the body’s own GH release; they do not contain GH.
Can they be combined? Yes, some protocols use No-DAC for daily pulses with weekly DAC for baseline elevation, though this is advanced research territory.
Related Reading
- CJC-1295 + Ipamorelin Combination Guide
- CJC-1295 vs Ipamorelin Comparison
- Growth Hormone-Releasing Peptides Guide
- Sermorelin (GHRH Analog) Guide
Shop Related Research Compounds
Browse our research catalog, including CJC-1295 with DAC, CJC-1295 No-DAC, and CJC-1295 + Ipamorelin Blend, all supplied with batch COAs.
Disclaimer: This article is for educational and research purposes only. CJC-1295 is a research compound not approved for general human use. Always consult qualified professionals regarding research protocols.
